Abstract
Treatments that are designed to reduce Alzheimer’s disease (AD) pathology may be most useful when given to subjects prior to a diagnosis of AD using current diagnostic criteria. These earlier patients may have early cognitive losses consistent with mild cognitive impairment (MCI) or may be completely asymptomatic. Screening and treatment programs for other disease states have been explored previously; these include cholesterol screening for cardiovascular disease, genetic screening for Huntington’s disease and screening for some types of cancer. Cancer screening and treatment programs have been developed for colon cancer, breast cancer and prostate cancer. Screening programs for these other disease states are briefly reviewed and are compared to preliminary modeling data describing a hypothetical screening and treatment program for AD. While primary prevention based on screening of asymptomatic individuals using biomarkers has broad appeal, secondary prevention employing treatment of patients with MCI may be more easily implemented.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 1984;34:939–944.
Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Geteau P, Jacqmin-Gadda H, Dartigues JF. Prodromal Alzheimer’s disease: Successive emergence of the clinical symptoms. Ann Neurol 2008:64:492–498.
Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142.
Dubois B, Feldman HF, Jacova C, DeKosky ST et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.
Grundman M, Petersen RC, Bennett D, et al. Alzheimer Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned? Alzheimer’s and Dementia 2006;2:220–233.
ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007;68:1–9.
Hayden MR. Predictive testing for Huntington’s disease: a universal model? Lancet Neurol 2003;2:141–142.
Cholesterol Treatment Trialist Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.
Weinberg DS. In the clinic: Colorectal cancer screening. Ann Intern Med 2008:ICT1–ICT16.
Levin B, Lieberman DA, McFarland B, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on colorectal cancer, and the American College of Radiology. Gastroenterology 2008;134:1570–1595.
Subramanian S, Bobashev G, Morris RJ. Modeling the cost-effectiveness of colorectal cancer screening: Policy guidance based on pateint preferences and compliance. Cancer Epidemiol Biomarkers Prev 2009;18:1971–1978.
Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685–1692.
Qaseem A, Snow V, Sherif K, et al. Screening mammography for women 40 to 49years of age: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;146:522–525.
Mandelblatt JS, Schechter CB, Vabroff R, et. al. Toward optimal screening strategies for older women: Costs, benefits, and harms of breast cancer screening aby age, biology and health status. J Gen Intern Med 2005;20:487–496.
U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;151:716–726.
Barry MJ. Screening for prostate cancer — the controversy that refuses to die. NEJM 2009;360:1351–1354.
Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–1328.
Andriole GL, Grubb RL, Buys SS, et. al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Kahle-Wrobleski K, Siemers ER, Callahan CM, Sarpong EM, Furiak NM, Klein TM, Klein RW. Biomarker Screening for Alzheimer’s Disease: The Impact of Sensitivity and Specificity Parameters. American Academy of Neurology 2009 annual meeting, Seattle, WA; P09. 119.
Kahle-Wrobleski K, Furiak N, Klein R, Klein T, Siemers E. Biomarker screening for Alzheimer’s disease: When to screen and how often? Alzheimer’s & Dementia 2009;5:P15.
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siemers, E. Designing clinical trials for early (pre-dementia) Alzheimer’s disease: Determining the appropriate population for treatment. J Nutr Health Aging 15, 22–24 (2011). https://doi.org/10.1007/s12603-011-0008-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-011-0008-6